Balchem Corp. Q1 2006 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2006. Balchem Corporation develops, manufactures, and distributes specialty performance ingredients for the food, pharmaceutical, feed, and medical sterilization industries. The Company operates through three segments: Specialty Products, Encapsulated/Nutritional Products, and BCP Ingredients.
Key Financial Metrics
| Metric (in thousands) | Q1 2006 | Q1 2005 |
|---|---|---|
| Net Sales | $24,597 | $19,340 |
| Gross Profit | $8,222 | $7,182 |
| Gross Margin % | 33.4% | 37.1% |
| Operating Income | $4,469 | $4,031 |
| Net Earnings | $2,858 | $2,568 |
| Diluted EPS | $0.24 | $0.21 |
| Cash from Operations | $4,199 | $3,548 |
| Cash & Equivalents (End Period) | $6,346 | $16,058 |
| Total Debt (Current + Long-term) | $7,250 | $0 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 27.2% to $24.6 million, driven by volume increases in ethylene oxide and propylene oxide, and the inclusion of new product lines from recent acquisitions.
- Acquisition Impact: On February 8, 2006, the Company acquired Chelated Minerals Corporation (CMC) for approximately $17.35 million. This transaction significantly increased goodwill (from $13.3M to $24.9M) and intangible assets.
- Margin Compression: Gross margin percentage declined from 37.1% to 33.4% due to product mix shifts and higher raw material and fuel costs.
- Debt Structure: The Company incurred $10 million in new term debt to fund the CMC acquisition, resulting in a jump in interest expense from $2,000 to $86,000.
- Accounting Change: Adoption of SFAS 123R (Share-Based Payment) effective Jan 1, 2006, resulted in a $262,000 non-cash stock compensation expense, reducing net earnings by $254,000 ($0.02 per share).
Outlook, Risks, and Management Commentary
- Liquidity: Cash and cash equivalents decreased by $6.65 million primarily due to the CMC acquisition. Working capital declined to $18.98 million. Management expects operations to generate sufficient cash flow for working capital and capital investments.
- Debt Servicing: The new term loan matures on March 1, 2009, with interest at LIBOR + 1.00%. A $3 million revolving credit facility is available but undrawn.
- Contingencies: The Company has a contingent payment obligation related to the 2005 Loders Croklaan asset acquisition based on future sales volume. No payments have been made as of March 31, 2006.
- License Agreement: A license agreement with Project Management and Development Co., Ltd. (PMD) for choline chloride technology in Saudi Arabia is ongoing, with revenue recognized on a percentage-of-completion basis.
- Internal Controls: Disclosure controls for the newly acquired CMC were excluded from the Q1 evaluation as the assessment is ongoing.
Investor Verification Checklist
- Verify the final purchase price allocation for the CMC acquisition, as the current figures are preliminary and subject to working capital adjustments.
- Monitor the impact of rising raw material and fuel costs on future gross margins, which compressed in Q1.
- Review the integration progress of CMC and the Loders Croklaan assets to ensure projected cost savings and revenue synergies are realized.
- Track the contingent consideration payments related to the Loders Croklaan acquisition over the next three years.
- Assess the Company's ability to service the new $10 million term loan while maintaining liquidity for future acquisitions.